drugset / Trial / NCT03184844

The Effective and Safety of Thalidomide in TI

NCT03184844 ↗

Phase 2 Unknown 100 enrolled Xiao-Lin Yin
NaSingle-groupOpen-labelTreatment

Summary

This is an exploratory experiment, aims to explore the effective and safety of thalidomide in the treatment of TI to improve the hemoglobin level, improve the quality of life, reduce blood transfusion, so as to avoid the adverse reactions caused by transfusion,60\~100 patients will be enrolled.

Timeline

Start
2017-05-02
Primary completion
2019-02-02
Completion
2019-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified 50 mg Oral

Indications